neladalkib

all catalysts(0)

nothing on the calendar yet

News(5)

• Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
  Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
  biopharma_dive · 22d ago
• GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
  GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…
  fiercebiotech · 23d ago
• GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
  Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…
  biospace · 28d ago
• GSK lung cancer drug gets speedy approval following $10.6B deal
  The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
  biopharma_dive · 29d ago
• GSK boosts cancer pipeline with $11B Nuvalent buyout
  The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
  biopharma_dive · 2mo ago